Objective
Glioblastoma multiforme (GBM) is the most prevalent deadly brain tumour and is currently incurable. Patients die from recurrent tumours that grow from cells surviving the first round of treatment. This is mainly due to the narrow therapeutic window of current drugs and to the low permeability of these drugs across the blood-brain barrier (BBB). Targeted non-viral delivery systems have shown great promise to decrease side effects of therapeutics and to enable the transport across biological barriers. The main objective in this proposal is to generate a dually targeted nanoparticle loaded with mRNA encoding a conditionally toxic protein to treat brain cancer. The nanoparticle will be modified with two ligands: an antibody for targeting tumour cells and a peptide that enables transport across the BBB. In addition, I will develop an acid-labile coating that enhances the stability of the polyplex in blood and is released upon internalization. This coating will present the ligands in a defined orientation using bioorthogonal chemistry, thereby maximising their targeting efficiency. The chemical handles will be introduced using genetic code expansion in the antibody and solid-phase synthesis in the peptide. A variety of formulations will be screened in vitro to evaluate their stability and transfection efficiency, and BBB permeability will be assessed in a human cell-based BBB model. Subsequently, the efficacy of the most promising candidates will be tested in a GBM mouse model. The combination of a polyplex having high transfection efficiency with a sheddable coating and oriented targeting ligands is designed to generate the first efficient non-viral gene delivery system for the systemic treatment of GBM, reaching all tumour cells to provide a more efficient treatment and potentially prevent recurrence.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- engineering and technology materials engineering coating and films
- medical and health sciences clinical medicine oncology
- engineering and technology nanotechnology nano-materials
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-ST - Standard EF
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2018
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
08017 Barcelona
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.